Dehydroepiandrosterone administration in treating medical and neuropsychiatric disorders high hopes, disappointing results, and topics for future research

Neuroactive Steroids in Brain Function, Behavior and Neuropsychiatric Disorders: Novel Strategies for Research and Treatment

Volumn , Issue , 2008, Pages 337-368

  Ritsner, Michael S ^a  

^a SHA'AR MENASHE MENTAL HEALTH CENTER   (Israel)

Author keywords

anxiety; cognition; Dehydroepiandrosterone; dehydroepiandrosterone sulfate; depression; medical disorders; schizophrenia; side effects; treatment

Indexed keywords

EID: 84892086395     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4020-6854-6_17     Document Type: Chapter

References (132)

1. Young J, Couzinet B, Nahoul K, et al. Panhypopituitarism as a model to study the metabolism of dehydroepiandrosterone (DHEA) in humans. J Clin Endocrinol Metab 1997;82:2578-2585.
2. Morales AJ, Haubrich RH, Hwang JY, et al. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf) 1998;49:421-432.
3. Casson PR, Santoro N, Elkind-Hirsch K, et al. Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial. Fertil Steril 1998;70:107-110.
4. Arlt W, Justl HG, Callies F, et al. Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. J Clin Endocrinol Metab 1998;83:1928-1934.
5. Arlt W, Callies F, Van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 1999;341:1013-1020.
6. Mortola JF, Yen SS. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab 1990;71:696-704.
7. Nestler JE, Barlascini CO, Clore JN, Blackard WG. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab 1988;66:57-61.
8. Genazzani AD, Lanzoni C, Genazzani AR. Might DHEA be considered a beneficial replacement therapy in the elderly? Drugs Aging 2007;24(3):173-185.
9. Obut TA, Ovsyukova MV, Cherkasova OP. Prolonged decrease in stress reactivity caused by dehydroepiandrosterone sulfate. Bull Exp Biol Med. 2006;141:571-573.
10. 1) receptor mediated antidepressant-like effects of neurosteroids in the Porsolt forced swim test. Neuroreport 1998;9:3069-3073.
11. 1-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J Pharmacol Exp Ther 2001;298:1269-1279.
12. Flood JF, Roberts E. Dehydroepiandrosterone sulphate proves memory in aging mice. Brain Res 1998;448:178-181.
13. Fedotova J, Sapronov N. Behavioral effects of dehydroepiandrosterone in adult male rats. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:1023-7.
14. Juhasz-Vedres G, Rozsa E, Rakos G, et al. Dehydroepiandrosterone sulfate is neuroprotective when administered either before or after injury in a focal cortical cold lesion model. Endocrinology 2006;147:683-686.
15. Tunez I, Munoz MC, et al. Treatment with dehydroepiandrosterone prevents oxidative stress induced by 3-nitropropionic acid in synaptosomes. Pharmacology 2005;74:113-118.
16. Pelissier MA, Trap C, Malewiak MI, Morfin R. Antioxidant effects of dehydroepiandrosterone and 7alpha-hydroxy-dehydroepiandrosterone in the rat colon, intestine and liver. Steroids 2004;69:137-144.
17. Patel MA, Katyare SS. Dehydroepiandrosterone (DHEA) treatment stimulates oxidative energy metabolism in the cerebral mitochondria from developing rats. Int J Dev Neurosci 2006;24:327-334.
18. Patel MA, Katyare SS. Effect of dehydroepiandrosterone (DHEA) treatment on oxidative energy metabolism in rat liver and brain mitochondria. A dose-response study. Clin Biochem 2007;40:57-65.
19. Patel MA, Katyare SS. Treatment with dehydroepiandrosterone (DHEA) stimulates oxidative energy metabolism in the cerebral mitochondria. A comparative study of effects in old and young adult rats. Neurosci Lett 2006;402:131-136.
20. MacEwen EG, Kurzmann ID. Obesity in the dog: role of the adrenal steroid dehydroepiandrosterone. J Nutr 1991;121:51-55.
21. Yen TT, Allan JV, Pearson DV. Prevention of obesity in Avy/A mice by dehydroepiandrosterone. Lipids 1997;12:409-413.
22. Rontzsch A, Thoss K, Petrow PK, et al. Amelioration of murine antigen-induced arthritis by dehydroepiandrosterone (DHEA). Inflamm Res 2004;53:189-198.
23. Wang L, Wang YD, Wang WJ, et al. Dehydroepiandrosterone improves murine osteoblast growth and bone tissue morphometry via mitogen-activated protein kinase signaling pathway independent of either androgen receptor or estrogen receptor. J Mol Endocrinol 2007;38:467-479.
24. Schwartz AG, Pashko LL. Cancer chemoprevention with the adrenocortical steroid dehydroepiandrosterone and structural analogs. J Cell Biochem 1995;22(Suppl):210-217.
25. Schwartz AG, Pashko LL. Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev 2004;3:171-187.
26. Shilkaitis A, Green A, Punj V, et al. Dehydroepiandrosterone inhibits the progression phase of mammary carcinogenesis by inducing cellular senescence via a p16-dependent but p53-independent mechanism. Breast Cancer Res. 2005;7:R1132-R1140.
27. Ravid D, Fridman L, Gispan-Herman I, Maayan R, et al. DHEA, a neurosteroid, decreases cocaine self-administration and reinstatement of cocaine-seeking behavior in rats. Neuropsychopharmacology. 2006;31:2231-2236.
28. Kroboth PD, Salek FS, Pittenger AL, et al. DHEA and DHEA-S: a review. J Clin Pharmacol. 1999;39:327-348.
29. Huppert F, Van Niekerk J. WITHDRAWN: Dehydroepiandrosterone (DHEA) supplementation for cognitive function. Cochrane Database Syst Rev 2007;18: CD000304.
30. Olech E, Merrill JT. DHEA supplementation: the claims in perspective. Cleve Clin J Med. 2005;72(11):965-966, 968, 970-971 passim.
31. Bovenberg SA, Van Uum SH, Hermus AR. Dehydroepiandrosterone administration in humans: evidence based? Neth J Med. 2005;63(8):300-304.
32. George O, Vallee M, Le Moal M, Mayo W. Neurosteroids and cholinergic systems: implications for sleep and cognitive processes and potential role of age-related changes. Psychopharmacology (Berl) 2006;186:402-413.
33. Arlt W. Dehydroepiandrosterone replacement therapy. Curr Opin Endocrin Diab 2006;13:291-305.
34. Nippoldt T B. Dehydroepiandrosterone supplements: bringing sense to sensational claims. Endocr Pract 1998;4:106-111.
35. Wolf OT, Neumann O, Hellhammer DH, et al. Effects of a two-week physiological dehydroepiandrosterone substitution on neurocognitive performance and well-being in healthy elderly women and men. J Clin Endocrinol Metab 1997;82:2363-2367.
36. Wolf OT, Naumann E, Hellhammer DH, Kirschbaum C. Effects of dehydroepiandrosterone (DHEA) replacement in elderly men on event related potentials (ERPs), memory and wellbeing. J Gerontol A Biol Sci Med Sci 1998;53:385-390.
37. Kudielka BM, Hellhammer J, Hellhammer DH, et al. Sex differences in endocrine and psychological responses to psychosocial stress in healthy elderly subjects and the impact of a 2-week dehydroepiandrosterone treatment. J Clin Endocrinol Metab 1998;83:1756-1761.
38. Morales AJ, Nolan JJ, Nelson JC, et al. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994;78:1360-1367.
39. Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL, et al. Dehydroepiandrosterone replacement in aging humans. J Clin Endocrinol Metab 1999;84:1527-1533.
40. Van Niekerk JK, Huppert FA, et al. Salivary cortisol and DHEA: association with measures of cognition and well-being in normal older men, and effects of three months of DHEA supplementation. Psychoneuroendocrinology 2001;26:591-612.
41. Arlt W, Callies F, Koehler I, et al. Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. J Clin Endocrinol Metab 2001;86:4686-4692.
42. Gurnell EM, Chatterjee VK. Dehydroepiandrosterone replacement therapy. Eur J Endocrinol 2001;145:103-106.
43. Allolio B, Arlt W. DHEA treatment: myth or reality? Trends Endocrinol Metab 2002;13:288-294.
44. Kahn AJ, Haloran B. Dehydroepiandrosterone supplementation and bone turnover in middleaged to elderly men. J Clin Endocrinol Metab 2002;87:1544-1549.
45. Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA 2004;292:2243-2248.
46. Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA 2000;97:4279-4284.
47. Villareal DT, Holloszy JO, Kohrt WM. Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. Clin Endocrinol (Oxf) 2000;53:561-568.
48. Jankowski CM, Gozansky WS, et al. Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trial. J Clin Endocrinol Metab 2006;91:2986-2993.
49. Genazzani AR, Inglese S, Lombardi I, et al. Long-term low-dose dehydroepiandrosterone replacement therapy in aging males with partial androgen deficiency. Aging Male 2004;7:133-143.
50. Reiter WJ, Pycha A, Schatzl G, et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective double-blind, randomized, placebo-controlled study. Urology 1999;53:590-595.
51. Stomati M, Monteleone P, Casarosa E, et al. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause. Gynecol Endocrinol 2000;14:342-363.
52. Finckh A, Berner IC, Aubry-Rozier B, et al. A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. J Rheumatol 2005;32:1336-1340.
53. Genazzani AD, Stomati M, Bernardi F, et al. Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids. Fertil Steril 2003;80:1495-1501.
54. Genazzani AD, Pluchino N, Begliuomini S, et al. Long-term low-dose oral administration of dehydroepiandrosterone modulates adrenal response to adrenocorticotropic hormone in early and late postmenopausal women. Gynecological Endocrinology 2006;22:627-635.
55. Arlt W. Dehydroepiandrosterone replacement therapy. Seminars in Reproductive Medicine 2004;22:379-388.
56. Saad F, Hoesl CE, et al. Dehydroepiandrosterone treatment in the aging male-what should the urologist know? Eur Urol 2005;48:724-733.
57. Grimley Evans J, Malouf R, et al. Dehydroepiandrosterone (DHEA) supplementation for cognitive function in healthy elderly people. Cochrane Database Syst Rev 2006;Oct.(4):CD006221.
58. Panjari M, Davis SR. DHEA therapy for women: effect on sexual function and wellbeing. Hum Reprod Update 2007;13:239-248.
59. Sugino M, Ohsawa N, Ito T, et al. A pilot study of dehydroepiandrosterone sulfate in myotonic dystrophy. Neurology 1998;51:586-589.
60. Van Vollenhoven RF. Dehydroepiandrosterone for the treatment of systemic lupus erythematosus. Expert Opin Pharmacother 2002;3:23-31.
61. Nordmark G, Bengtsson C, Larsson A, et al. Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus. Autoimmunity 2005;38:531-540.
62. Sun Y, Mao M, Sun L, et al. Treatment of osteoporosis in men using dehydroepiandrosterone sulfate. Chin Med J 2002;115:402-404.
63. Piketty C, Jayle D, Leplege A, et al. Double-blind placebo-controlled trial of oral dehydroepiandrosterone in patients with advanced HIV disease. Clin Endocrinol 2001;55:325-330.
64. Brooke AM, Kalingag LA, et al. Dehydroepiandrosterone improves psychological well-being in male and female hypopituitary patients on maintenance growth hormone replacement. J Clin Endocrinol Metab 2006;91:3773-3779.
65. Binello E, Gordon CM. Clinical uses and misuses of dehydroepiandrosterone. Curr Opin Pharmacol 2003;3:635-641.
66. Arlt W, Haas J, Callies F. Biotransformation of oral dehydroepiandrosterone in elderly men: Significant increase in circulating estrogens. J Clin Endocrinol Metab 1999;84:2170-2176.
67. Hunt PJ, Gurnell EM, Huppert FA, et al. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. J Clin Endocrinol Metab 2000;85:4650-4656.
68. Arlt W, Callies F, Allolio B. Gynecol Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause. Endocrinol 2000;14:342-363.
69. Libe R, Barbetta L, et al. Effects of dehydroepiandrosterone (DHEA) supplementation on hormonal, metabolic and behavioral status in patients with hypoadrenalism. J Endocrinol Invest 2004;27:736-741.
70. Stoffel-Wagner B. Neurosteroid metabolism in the human brain. Eur J Endocrinol 2001;145:669-679.
71. Stoffel-Wagner B. Neurosteroid biosynthesis in the human brain and its clinical implications. Ann NY Acad Sci 2003;1007:64-78.
72. Pisu MG, Serra M. Neurosteroids and neuroactive drugs in mental disorders. Life Sci 2004;74:3181-3197.
73. Majewska MD, Demirgoren S, Spivak CE, London ED. The neurosteroid dehydroepiandrosterone sulfate is an allosteric antagonist of the GABAA receptor. Brain Res 1990;526:143-146.
74. Demirgoren S, Majewska MD, Spivak CE, London ED. Receptor binding and electrophysiological effects of dehydroepiandrosterone sulfate, an antagonist of the GABAA receptor. Neuroscience 1991;45:127-135.
75. Bergeron R, De Montigny C, Debonnel G. Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors. J Neurosci 1996;16:1193-1202.
76. Wolkowitz OM, Reus VI, et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatry 1997;41:311-318.
77. Wolkowitz OM, Reus VI, Keebler A, et al. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry 1999;156:646-649.
78. Schmidt PJ, Daly RC, Bloch M, et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry 2005;62:154-162.
79. Hsiao CC. Difference in pre- and post-treatment plasma DHEA levels were significantly and positively correlated with difference in pre- and post-treatment Hamilton depression scores following successful therapy for major depression. Psychoneuroendocrinology 2006;31:839-846.
80. Bloch M, Schmidt PJ, Danaceau MA, Adams LF, Rubinow DR. Dehydroepiandrosterone treatment of midlife dysthymia. Biol Psychiatry 1999;45:1533-1541.
81. Rabkin JG, McElhiney MC, et al. Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS. Am J Psychiatry 2006;163:59-66.
82. Brebner K, Hayley S, Zacharko R, Merali Z, Anisman H. Synergistic effects of interleukin-1beta, interleukin-6 and tumor necrosis factor-alpha: central monoamine, corticosterone, and behavioral variations. Neuropsychopharmacology 2000;22:566-580.
83. Strous RD, Maayan R, Lapidus R, et al. Value of Dehydroepiandrosterone (DHEA) Augmentation in the Management of Negative Symptoms in Schizophrenia. Arch Gen Psychiatry 2003;60:133-141.
84. Strous RD, Stryjer R, Maayan R, et al. Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Psychoneuroendocrinology 2007;32:96-105.
85. Nachshoni T, Ebert T, Abramovitch Y, et al. Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Schizophr Res 2005;79:251-256.
86. Ritsner MS, Gibel A, Ratner Y, et al. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychopharmacol 2006;26:495-499.
87. Welham J, Stedman T, Clair A. Choosing negative symptom instruments: issues of representation and redundancy. Psychiatry Res 1999;87:47-56.
88. Norman RM, Malla AK, et al. A study of the interrelationship between and comparative interrater reliability of the SAPS, SANS and PANSS. Schizophr Res 1996;19:73-85.
89. Spalletta G, Pasini A, et al. Patients with deficit, nondeficit, and negative symptom schizophrenia: do they differ during episodes of acute psychotic decompensation? Schizophr Res 1997;24:341-348.
90. Galynker I, Cohen L, et al. Psychiatric symptom severity and length of stay on an intensive rehabilitation unit. Psychosomatics 2000;41:114-120.
91. Smith RC, Infante M, et al. Effects of Cigarette Smoking on Psychopathology Scores in Patients With Schizophrenia: An Experimental Study. Subst Abus 2001;22:175-186.
92. Feldman PD, Kaiser CJ, et al. Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. J Clin Psychiatry 2003;64:998-1004.
93. Ritsner M, Maayan R, Gibel A, et al. Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients. Eur Neuropsychopharmacol 2004;14:267-273.
94. Strous RD, Maayan R, Lapidus R, et al., Increased circulatory dehydroepiandrosterone and dehydroepiandrosterone-sulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatology. Schizophr Res 2004;71:427-434.
95. Di Michele F, Caltagirone C, Bonaviri G, et al. Plasma dehydroepiandrosterone levels are strongly increased in schizophrenia. J Psychiatr Res 2005;39:267-273.
96. Johnson M, Bebb R, Sirrs S. Uses of DHEA in aging and other disease states. Ageing Res Rev 2002;1:29-41.
97. Ritsner M, Gibel A, Ratner Y. Determinants of changes in perceived quality of life in the course of schizophrenia. Qual Life Res 2006;15:515-526.
98. Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 2006;67(Suppl 9):3-8; discussion 36-42.
99. Alhaj HA, Massey AE, McAllister-Williams RH. Effects of DHEA administration on episodic memory, cortisol and mood in healthy young men: a double-blind, placebo-controlled study. Psychopharmacology 2006;188:541-551.
100. Wolkowitz OM, Kramer JH, Reus VI, et al. DHEA treatment of Alzheimer's disease: a randomized, double-blind, placebo-controlled study. Neurology 2003;60:1071-1076.
101. Parsons TD, Kratz KM, et al. Dhea supplementation and cognition in postmenopausal women. Int J Neurosci 2006;116:141-155.
102. Ritsner MS, Blumenkrantz H, Dubinsky T, Dwolatzky T. The detection of neurocognitive decline in schizophrenia using the Mindstreams Computerized Cognitive Test Battery. Schizophr Res 2006;82:39-49.
103. Butler PD, Schechter I, Zemon V, et al. Dysfunction of early-stage visual processing in schizophrenia. Am J Psychiatry 2001;158:1126-1133.
104. Butler PD, Zemon V, Schechter I, et al. Early-stage visual processing and cortical amplification deficits in schizophrenia. Arch Gen Psychiatry 2005;62:495-504.
105. Butler PD, Martinez A, Foxe JJ, et al. Subcortical visual dysfunction in schizophrenia drives secondary cortical impairments. Brain 2007;130:417-430.
106. Uhlhaas PJ, Phillips WA, Silverstein SM. The course and clinical correlates of dysfunctions in visual perceptual organization in schizophrenia during the remission of psychotic symptoms. Schizophr Res 2005;75:183-192.
107. Lee TM, Cheung PP. The relationship between visual-perception and attention in Chinese with schizophrenia. Schizophr Res 2005;72:185-193.
108. Prouteau A, Verdoux H, Briand C, et al. The crucial role of sustained attention in community functioning in outpatients with schizophrenia. Psychiatry Res 2004;129:171-177.
109. Moghaddam B. Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders. Biol Psychiatry 2002;51:775-787.
110. Reuter B, Kathmann N. Using saccade tasks as a tool to analyze executive dysfunctions in schizophrenia. Acta Psychol (Amst) 2004;115:255-269.
111. Fiszdon JM, Choi J, Bryson GJ, Bell MD. Impact of intellectual status on response to cognitive task training in patients with schizophrenia. Schizophr Res 2006;87:261-269.
112. Bellino S, Rocca P, Patria L, et al. Relationships of age at onset with clinical features and cognitive functions in a sample of schizophrenia patients. J Clin Psychiatry 2004;65:908-914.
113. Bozikas VP, Kosmidis MH, Kioperlidou K, Karavatos A. Relationship between psychopathology and cognitive functioning in schizophrenia. Compr Psychiatry 2004;45:392-400.
114. Brazo P, Delamillieure P, Morello R, et al. Impairments of executive/attentional functions in schizophrenia with primary and secondary negative symptoms. Psychiatry Res 2005;133:45-55.
115. Villalta-Gil V, Vilaplana M, Ochoa S, et al. Neurocognitive performance and negative symptoms: are they equal in explaining disability in schizophrenia outpatients? Schizophr Res 2006;87:246-253.
116. Weickert TW, Goldberg TE. First- and second-generation antipsychotic medication and cognitive processing in schizophrenia. Curr Psychiatry Rep 2005;7:304-310.
117. Kawai N, Yamakawa Y, Baba A, et al. High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1009-1114.
118. Yanase T, Fukahori M, Taniguchi S, et al. Serum dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEA-S) in Alzheimer's disease and in cerebrovascular dementia. Endocr J 1996;43:119-123.
119. Morrison MF, Redei E, Ten Have T, et al. Dehydroepiandrosterone sulfate and psychiatric measures in a frail, elderly residential care population. Biol Psychiatry 2000;47:144-150.
120. Vallee M, Mayo W, Le Moal M. Role of pregnenolone, dehydroepiandrosterone and their sulfate esters on learning and memory in cognitive aging. Brain Res Brain Res Rev 2001;37:301-312.
121. Harris DS, Wolkowitz OM, Reus VI. Movement disorder, memory, psychiatric symptoms and serum DHEA levels in schizophrenic and schizoaffective patients. World J Biol Psychiatry 2001;2:99-102.
122. Hintze, JL NCSS 2007. Statistical System for Windows. User's Guide. Number Cruncher Statistical Systems, Kaysville, Utah, 2006 (http://www.ncss.com) .
123. Lasco A, Frisina N, Morabito N, et al. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. Eur J Endocrinol 2001;145:457-461.
124. Strous RD, Maayan R, Kotler M, Weizman A. Hormonal profile effects following dehydroepiandrosterone (DHEA) administration to schizophrenic patients. Clin Neuropharmacol 2005;28:265-269.
125. Strous RD, Gibel A, Weizman A, Maayan R, Ritsner MS. Hormonal response on dehydroepiandrosterone administration in schizophrenia: findings from a randomized, double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol 2007 (in press).
126. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
127. White L, Harvey PD, Opler L, Lindenmayer JP. Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. The PANSS Study Group. Psychopathology 1997;30:263-274.
128. Guy W. ECDEU Assessment Manual for Psychopharmacology, revised. Washington, DC: US Department of Health, Education and Welfare, 1976.
129. Chouinard G, Ross-Chouinard A, Ann Annable L. Extrapyramidal Symptom Rating Scale. Can J Neurol Sci 1980;7:233.
130. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 2005;76:247-265.
131. Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit scale. Schizophr Bull 1984;10:388-398.
132. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993;29:321-326.